Đơn xin công nhận các nhà sản xuất nước ngoài lưu hành thuốc tại Nhật Bản. Xem thêm các tài liệu khác trên kênh của Công ty Cổ phần Tư vấn Thiết kế GMP EU
CDSCO & Central Bureau of Narcotics are the two organizations which regulate Narcotic Drugs.
ACCREDITED CONSULTANTS PVT LTD
info@acplgroupindia.co.in
+919310040434
1. This Decree provides for pharmacy practice certificate; pharmacy business; export and import of drugs; registration of herbal ingredients, excipients, capsule shells; assessment of overseas drug manufacturers; power, method and procedures for recalling medicinal ingredients; handling of recalled medicinal ingredients; documents and procedures for issuance of certification of drug advertisement and drug price management.
2. This Decree applies to organizations and individuals in Vietnam and overseas whose operation involves pharmacy in Vietnam.
the overall summary of regulation of herbal drugs in India and what document required for getting approval and summary of GMP, GCP guideline with labelling requirement.
Good regulatory practice are internationally recognized process, system, tools and method for improving the quality of regulation.
It includes
1)COMMUNITY PHARMACY RETAIL AND WHOLESALE PHARMACY
-Dacumentation
-Licenses
-Renewal
-E-governance
2) HOSPITAL PHARMACY
-Dacumentation
-Licenses
-Renewal
-E-governance
3) PHARMA MANIFACTURING
-Dacumentation
-Licenses
-Renewal
-E-governance
4) IMPORT OF DRUG AND MEDICAL DEVICE
-Dacumentation
-Licenses
-Renewal
-E-governance
5) EXPORT OF DRUG AND MEDICAL DEVICE
-Dacumentation
-Licenses
-Renewal
-E-governance
Indian regulatory requirements - industrial pharmacy 2Jafarali Masi
Indian Regulatory Requirements: Central Drug Standard Control Organization (CDSCO) and State Licensing Authority: Organization, Responsibilities, Certificate of Pharmaceutical Product (COPP), Regulatory requirements and approval procedures for New Drugs
Regulation Governing Clinical Trials In India,USA and Europe. KapilKumar198
This presentation contain detailed information about the "Regulation Governing Clinical Trials In India,USA and Europe".And about the clinical trails and medical devices regulations in India.
CDSCO & Central Bureau of Narcotics are the two organizations which regulate Narcotic Drugs.
ACCREDITED CONSULTANTS PVT LTD
info@acplgroupindia.co.in
+919310040434
1. This Decree provides for pharmacy practice certificate; pharmacy business; export and import of drugs; registration of herbal ingredients, excipients, capsule shells; assessment of overseas drug manufacturers; power, method and procedures for recalling medicinal ingredients; handling of recalled medicinal ingredients; documents and procedures for issuance of certification of drug advertisement and drug price management.
2. This Decree applies to organizations and individuals in Vietnam and overseas whose operation involves pharmacy in Vietnam.
the overall summary of regulation of herbal drugs in India and what document required for getting approval and summary of GMP, GCP guideline with labelling requirement.
Good regulatory practice are internationally recognized process, system, tools and method for improving the quality of regulation.
It includes
1)COMMUNITY PHARMACY RETAIL AND WHOLESALE PHARMACY
-Dacumentation
-Licenses
-Renewal
-E-governance
2) HOSPITAL PHARMACY
-Dacumentation
-Licenses
-Renewal
-E-governance
3) PHARMA MANIFACTURING
-Dacumentation
-Licenses
-Renewal
-E-governance
4) IMPORT OF DRUG AND MEDICAL DEVICE
-Dacumentation
-Licenses
-Renewal
-E-governance
5) EXPORT OF DRUG AND MEDICAL DEVICE
-Dacumentation
-Licenses
-Renewal
-E-governance
Indian regulatory requirements - industrial pharmacy 2Jafarali Masi
Indian Regulatory Requirements: Central Drug Standard Control Organization (CDSCO) and State Licensing Authority: Organization, Responsibilities, Certificate of Pharmaceutical Product (COPP), Regulatory requirements and approval procedures for New Drugs
Regulation Governing Clinical Trials In India,USA and Europe. KapilKumar198
This presentation contain detailed information about the "Regulation Governing Clinical Trials In India,USA and Europe".And about the clinical trails and medical devices regulations in India.
Danh mục 37 thuốc sản xuất trong nước được cấp giấy phép lưu hành tại Việt Nam - Đợt 185.
Quyết định được Cục Quản lý Dược Việt Nam ban hành vào tháng 7 năm 2023.
Danh mục 259 thuốc sản xuất trong nước được cấp giấy đăng ký lưu hành tại Việt Nam - Đợt 185.
Danh mục được ban hành bới Cục Quản lý Dược Việt Nam tháng 7 năm 2023.
Ngày 21/06 vừa qua, cục Quản lý Dược vừa ban hành quyết định về việc công bố danh mục thuốc biệt dược gốc - đợt 2 năm 2023.
Ban hành kèm theo quyết định này bao gồm 83 thuốc biệt dược gốc.
Xem thêm các tài liệu khác trên trang của công ty cổ phần Tư vấn thiết kế GMP-EU.
Hướng dẫn thực hành này cung cấp thông tin cho các nhà sản xuất thức ăn có chất sát khuẩn không an toàn do thuốc chuyển sang thức ăn chăn nuôi không chứa thuốc hoặc một loại thức ăn khác. Mục đích của hướng dẫn này:
• “Sản xuất và phân phối thức ăn có chứa thuốc” đề cập đến việc sử dụng thiết bị để sản xuất, chế biến, đóng gói, giữ và phân phối thức ăn.
• “Thức ăn chăn nuôi” được sản xuất có thêm hóa chất bảo quản. Thức ăn cho động vật như vậy có thể được gọi trong hướng dẫn này là “thức ăn có tẩm thuốc” hoặc “thức ăn không có tẩm thuốc”, tùy thuộc vào việc thức ăn đó có được pha chế để chứa một loại thuốc mới dành cho động vật hay không. Để thuận tiện, chúng tôi gọi những loại thuốc mới dành cho động vật này đơn giản là “thuốc”.
• “Thuốc mang theo” đề cập đến sự hiện diện của thuốc trong lô thức ăn chăn nuôi tiếp theo.
• “Ô nhiễm không an toàn”: đề cập đến mức độ nhiễm bẩn, do một loại thuốc được phép sử dụng trong thức ăn chăn nuôi, gây ra rủi ro không thể chấp nhận được đối với sức khỏe con người hoặc động vật.
Nói chung, các tài liệu hướng dẫn của FDA không thiết lập các trách nhiệm có thể thực thi về mặt pháp lý. Thay vào đó nó mô tả Cơ quan về một chủ đề và chỉ nên được xem dưới dạng khuyến nghị, trừ khi các yêu cầu pháp lý hoặc quy định cụ thể được trích dẫn. Việc sử dụng từ nên trong hướng dẫn của Cơ quan có nghĩa là điều gì đó được gợi ý hoặc khuyến nghị, nhưng không bắt buộc.
Xem thêm các tài liệu khác trên trang của công ty cổ phần tư vấn thiết kể GMP EU.
Cục Quản lý Thực phẩm và Dược phẩm Hoa Kỳ đưa ra hướng dẫn cho các nhà sản xuất và phân phối sữa cho trẻ sơ sinh về các yêu cầu ghi nhãn nhất định đối với các sản phẩm này. Hướng dẫn này đặc biệt chú trọng đến số lượng các công thức sữa cho trẻ sơ sinh có bao bì tương tự nhưng khác nhau về thành phần hoặc mục đích sử dụng. Ngày càng nhiều các sản phẩm ghi sai nhãn về hàm lượng chất dinh dưỡng, do vậy hướng dẫn này cung cấp thông tin có thể giúp các nhà sản xuất hiểu và tuân thủ các yêu cầu ghi nhãn liên quan.
Hướng dẫn này không bao gồm đầy đủ tất cả các quy định liên quan đến việc ghi nhãn sữa công thức dành cho trẻ sơ sinh. Vì vậy bạn có thể xem thêm các hướng dẫn khác tại www.fda.gov/FoodGuidances hoặc các tài liệu trên kênh của công ty cổ phần tư vấn thiết kế GMP EU.
Ngày 25/05 vừa qua, Cục quản lý Dược vừa ban hành danh mục 69 thuốc sản xuất trong nước được cấp giấy đăng ký lưu hành tại Việt Nam - Đợt 184.
Theo đó, ban hành kèm theo Quyết định này danh mục 69 thuốc sản xuất trong nước được cấp giấy đăng ký lưu hành tại Việt Nam - Đợt 184, cụ thể:
1. Danh mục 64 thuốc sản xuất trong nước được cấp giấy đăng ký lưu hành tại Việt Nam hiệu lực 05 năm (Phụ lục I kèm theo).
2. Danh mục 05 thuốc sản xuất trong nước được cấp giấy đăng ký lưu hành tại Việt Nam hiệu lực 03 năm (Phụ lục II kèm theo).
Xem thêm các tài liệu khác trên trang của công tư cổ phần tư vấn thiết kế GMP EU.
Ngày 25/05 vừa qua, Cục quản lý Dược đã ban hành quyết định số 352/QĐ-QLD về việc ban hành danh mục 231 thuốc nước ngoài được cấp, gia hạn giấy đăng ký lưu hành tại Việt Nam - Đợt 184.
Theo đề nghị của Trưởng phòng Đăng ký thuốc, Cục Quản lý Dược quyết định:
Ban hành kèm theo Quyết định này danh mục 231 thuốc sản xuất trong nước được cấp giấy đăng ký lưu hành tại Việt Nam - Đợt 184, cụ thể:
1. Danh mục 172 thuốc sản xuất trong nước được gia hạn giấy đăng ký lưu hành hiệu lực 05 năm (Phụ lục I kèm theo).
2. Danh mục 52 thuốc sản xuất trong nước được gia hạn giấy đăng ký lưu hành hiệu lực 03 năm (Phụ lục II kèm theo).
3. Danh mục 07 thuốc sản xuất trong nước được gia hạn đăng ký lưu hành đến 31/12/2025 (Phụ lục III kèm theo).
Xem thêm các tài liệu khác trên trang của công ty cổ phần Tư vấn thiết kế GMP EU.
Ngày 26/05 vừa qua, Cục Quản lý Dược đã ban hành quyết định số 371/QĐ-QLD về việc công bố danh mục thuốc biệt dược gốc Đợt 1 - năm 2023.
Theo đề nghị của Trưởng phòng Đăng ký thuốc - Cục Quản lý Dược, quyết định:
Công bố Danh mục 56 thuốc Biệt dược gốc Đợt 1 - Năm 2023 tại Phụ lục kèm theo Quyết định này.
Xem thêm các tài liệu khác trên trang của công ty cổ phần Tư vấn thiết kế GMP EU.
Ngày 26/05 vừa qua, Cục Quản lý Dược vừa ra quyết định số 370/QĐ-QLD về việc ban hành danh mục 50 thuốc nước ngoài được cấp, gia hạn giấy đăng ký lưu hành tại Việt Nam - Đợt 111 bổ sung.
Theo đề nghị của Trưởng phòng Đăng ký thuốc - Cục Quản lý Dược quyết định:
Ban hành kèm theo Quyết định này danh mục 50 thuốc nước ngoài được cấp, gia hạn giấy đăng ký lưu hành tại Việt Nam - Đợt 111 bổ sung, bao gồm:
1. Danh mục 41 thuốc nước ngoài được cấp giấy đăng ký lưu hành hiệu lực 05 năm - Đợt 111 bổ sung (tại Phụ lục I kèm theo).
2. Danh mục 01 thuốc nước ngoài được cấp giấy đăng ký lưu hành hiệu lực 03 năm - Đợt 111 bổ sung (tại Phụ lục II kèm theo).
3. Danh mục 07 thuốc nước ngoài được gia hạn giấy đăng ký lưu hành hiệu lực 05 năm - Đợt 111 bổ sung (tại Phụ lục III kèm theo).
4. Danh mục 01 thuốc nước ngoài được gia hạn giấy đăng ký lưu hành đến 31/12/2025 - Đợt 111 bổ sung (tại Phụ lục IV kèm theo).
Ngày 24/05 vừa qua, Bộ Y tế vừa ban hành quyết định về việc công bố danh mục thuốc có chứng minh tương đương sinh học đợt 2 - năm 2023.
Theo đề nghị của Trưởng phòng Đăng ký thuốc - Cục quản lý Dược, quyết định:
Công bố Danh mục 28 thuốc có chứng minh tương đương sinh học Đợt 2 - Năm 2023 tại Phụ lục kèm theo Quyết định này.
Xem thêm các tài liệu khác của Công ty cổ phần Tư vấn thiết kế GMP EU.
More from Công ty Cổ phần Tư vấn Thiết kế GMP EU (20)
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
NVBDCP.pptx Nation vector borne disease control program
Đơn xin công nhận các nhà sản xuất nước ngoài lưu hành thuốc tại Nhật Bản
1. 1
Application for Accreditation of Foreign Manufacturers
(This English document is only for reference purpose. In case of any discrepancy, the Japanese
text shall prevail. For further information, please contact Ministry of Health, Labour and Welfare
(MHLW) or PMDA.)
1. What is Accreditation of Foreign Manufacturers?
A foreign manufacturer (a person/a company) intending to manufacture drugs, quasi-
drugs, or medical devices in foreign countries and export them to Japan, is required to
be accredited by the Minister of Health, Labour, and Welfare as an “Accredited Foreign
Manufacturer”, specified in Article 13-3 of PAL, in the same way that a Japanese
manufacturer is licensed. The person or the company who intends to apply for the
accreditation is hereinafter referred to as an “Applicant”.
However, a foreign manufacturer of the drug or medical device, etc. whose marketing
approval holder has an effective importing license granted under the old PAL as of April
1, 2005, is deemed to be temporarily accredited under the revised PAL by the end of its
effective period. The manufacturer satisfying the above condition is hereinafter
referred to as a “Deemed Accredited Foreign Manufacturer”.
In addition, a foreign manufacturer intending to manufacture only drug substances to be
exported to Japan also need to obtain accreditation as an “Accredited Foreign
Manufacturer”. The Minister of Health, Labour and Welfare has an authority to grant
accreditation to a foreign manufacturer, while PMDAexamines buildings and facilities of
the manufacturing establishment for accreditation. The accreditation is granted for
each manufacturing establishment according to the category specified by the
Enforcement Regulations.
Before applying for accreditation, a Japanese marketing approval holder for an
“Applicant” needs to submit “Business Number Registration Form”, reporting information
on the applicant’s business and manufacturing establishments, in order to obtain
“Business Number”.
2. Application for Accreditation of ForeignManufacturers
(1) An “Applicant” is required to submit “Application for Accreditation” (Form No. 18 in
the PAL Enforcement Regulations) that is addressed to the Minister in duplicate,
and “Application for Accreditation Examination” (Form No.16-(2) in the Regulations)
to Chief Executive of PMDA. Both applications need to be submitted to
Administration Division II, Office of Review Administration of PMDA.
A Japanese marketing approval holder who markets drugs and medical devices, etc.
2. 2
manufactured by a foreign manufacturer can make an accreditation application on
the manufacturer’s behalf. However, the space of “Name of Applicant” on the
application form should be filled out with the foreign manufacturer’s name (when an
“Applicant” is a corporation, names of the corporation and their CEO). In addition,
an “Applicant” is to be responsible to renew their accreditation every 5 years. For
more details on the renewal procedure, please refer to 2-(4), “Application for
Renewal of Accreditation of Foreign Manufacturers”.
Examination Fees for the accreditation differ between on-site and document
examinations. However, PMDA requires only document audit fee to be paid to our
bank account because, in principle, we do not conduct on-site inspection only for the
purpose of examining buildings and facilities of a foreign manufacturing
establishment to be accredited.
A target period to complete administrative processing (standard administrative
process time) of accrediting a foreign manufacturer is not specifically set. However,
the period can be estimated to be about 5 months because the Minister’s licensing
process for a domestic manufacturing establishment takes about 5 months.
When an “Applicant” intends to apply for a new accreditation, they cannot apply for
multiple categories in one accreditation application. They need to submit an
accreditation application for one category and, at the same time, submit additional
applications for the other categories (ref. 2-(3), Application for Change/Addition in
Category of Accreditation of Foreign Manufacturers).
(2) Documents to Be Attached to Accreditation Application (Article 35, Paragraph
2 of the PAL Enforcement Regulations)
Ⓒ ”A medical certificate from a physician which indicates whether or not an “Applicant”
has mental disorders or is addicted to narcotics, cannabis, opium or stimulant drugs”.
(When the “Applicant” is a corporation, medical certificates of their CEO and all the
executives responsible for the services are required.)
A medical certificate and the other required documents for accreditation can be
written in any language, but their Japanese translations are required. The
reference of translator is needed only when they are written in other languages than
English.
When the “Applicant” is a corporation, and the Minister of Health Labour and
Welfare recognizes that the above medical certificate form a physician is not an
absolute necessity taking the responsible services of the executives into
3. 3
consideration, a signed written statement that the relevant executives are not fall
under item 3 (d) (excluding the provision of adult ward) and (e) of Article 5 of PAL
can be submitted.
Ⓒ “A curriculum vitae of the person who is responsible to the manufacturing
establishment”
Ⓒ “List of products” to be manufactured for exporting to Japan and “Documents on
manufacturing process”
Please make a list of products to be manufactured as detail as you can figure out by
the time of accreditation application. In a “Document on manufacturing process”,
please organize it clearly that each of the listed products will take what/which type of
manufacturing procedure at the relevant establishment.
④ “Adocument on buildings and facilities of a manufacturing establishment”
An “Applicant” intending to manufacture drugs (excluding in vitro diagnostics) and
quasi-drugs needs to submit documents equivalent to the application documents
for manufacturing license of drugs and quasi-drugs specified in “Enforcement of
Ministerial Ordinance etc. of Partial Revision of the Regulations for Manufacturing
Control and Quality Control of Drugs and Regulations for Buildings and Facilities for
Pharmacies, etc.” (PAB Notification No. 1332, dated October 9, 1980).
In addition, they need to submit informative documents for examination of buildings
and facilities of their manufacturing establishments such as a floor plan.
⑤ “When radiopharmaceuticals are included (excluding cases that the amount of
radiopharmaceuticals is equal to or less than those designated by the Minister), a
document on the type of the radiopharmaceuticals and outlines of facilities for
handling such radiopharmaceuticals”
⑥ “When a system for marketing license, manufacturing license, marketing approval or
marketing certification of drugs and medical devices or an equivalent system is
established in the country where the foreign manufacturer resides, a copy of the
license certificate issued by governmental organizations etc. of the country under
such system”. The license certificate should be currently valid.
Note 1: Points to Consider (PTC) with Respect to Accreditation of Foreign
4. 4
Manufacturers of Quasi-drugs
“A medical certificate for an “Applicant” from a physician” and “a curriculum vitae of
the person who is responsible for the foreign manufacturing establishment” do not
need to be attached to an application form for accreditation of foreign manufacturers,
when the marketing approval holder concerned responsibly ensures their reliability.
In this case, the “Applicant” can omit filling out the space of “Address” in the section
of “Person who is responsible for manufacturing establishment” and “Conditions of
Disqualification of applicant” on the application form.
In addition, the “Applicant” needs to indicate the status of their intended products by
showing either “Quasi-drug Subject to GMP” or “Quasi-drug Not Subject to GMP” in
the remarks column.
Note 2: Points to Consider (PTC) with Respect to Accreditation of Foreign
Manufacturers of Medical Devices and In vitro Diagnostics
When an “Applicant” has reasonable and convincing reasons why they have
difficulties to obtain their medical certificate from a physician in the country where
they reside, they can submit a written self-declaration instead of a medical
certificate.
(3) Application for Change/Addition in Categoryof Accreditation of Foreign
Manufacturers
When an “Accredited Foreign Manufacturer” changes the category accredited to
their manufacturing establishment or adds new categories to their accreditation,
they must submit a form, “Application for Change/Addition” (Form No. 21 specified in
the PAL Enforcement Regulations), in order to newly obtain the Minister’s
accreditation for the change or addition.
When the manufacturer intends to add new categories to their accreditation, they
need to apply for addition in accreditation category.
On the other hand, applying for change in category of accreditation allows the
manufacturer to be accredited to new categories while cancelling their previously
accredited categories.
In both of the cases, the manufacturer also needs to submit a form of “Application
for Accreditation Examination” (Form No. 16-(2) in the Regulations) in the same way
of a new application as referred to in 2-(1) above.
The documents required for change or addition in category of accreditation of
5. 5
foreign manufacturers are as follows; (Article 31 of the PAL Enforcement
Regulations shall apply mutatis mutandis to Article 37.)
1. Accreditation certificate
2. List of products whose accreditation category to be changed or added and
documents on their manufacturing processes
3. Documents on buildings and facilities of a manufacturing establishment that
relates to change or addition in category of accreditation
(4) Application for Renewal of Accreditation of Foreign Manufacturers
Unless an “Accredited Foreign Manufacturer” renews their accreditation, using a
form of “Application for Renewal of Accreditation” (Form No. 20 in the PAL
Enforcement Regulations), within its 5-year effective period, their accreditation
becomes null and void.
In renewing granted accreditation, they also need to submit a form of “Application for
Accreditation Examination” (Form No. 16-(2) in the Regulations) in the same way to
a new application as referred to in 2-(1) above.
When a “Deemed Accredited Foreign Manufacturer” applies for the first renewal of
their deemed accreditation after revision of the PAL, they need to attach a copy of
the certificate for their importing license, which was granted under the old PAL to
their Japanese importer called marketing approval holder under the new PAL, in
addition to take the same procedure as to obtain a new accreditation. On the other
hand, when an “Accredited Foreign Manufacturer” renews their accreditation
granted under the new PAL, they need to attach the certificate for their accreditation
to an application form for its renewal.
3. Others
(1) Notification on Change (Article 100 of the PAL Enforcement Regulations)
When an “(Deemed) Accredited Foreign Manufacturer” makes changes in the
following matters, they must notify the fact to the Minister within 30 days by
submitting a notification (Form No. 6) to PMDA.
Ⓒ Name or address of the person responsible for the manufacturing establishment
Ⓒ Name of the executives responsible for the services, when the manufacturer is a
corporation
Ⓒ Name of the manufacturing establishment
④ Major part of buildings and facilities of the manufacturing establishment
6. 6
⑤ Category and (deemed) accreditation number, when a foreign manufacturer
obtains additional accreditations for another category, or discontinues operation
of their accredited manufacturing establishment
(2) Advising Division/Office with respect toApplication for Accreditations
1. General questions on applications and Inquiries about review status
Administration Division II, Office of Review Administration
FAX: +81-3-3506-9442
2. Examination of buildings and facilities of manufacturing establishment to be
accredited
GMP Inspection Division, Office of Compliance and Standards
(Pharmaceuticals excluding In vitro diagnostics and quasi-drugs)
FAX: +81-3-3506-9465
Medical Device Quality System Inspection Division, Office of Compliance and
Standards
(Medical devices and In vitro diagnostics)
FAX: +81-3-3506-9465
4. References(Notification and Related Documents)
“Enforcement of Ministry Ordinances Regarding Revision of Regulations on
Manufacturing and Quality Control/Assurance of Drugs and Regulations on
Buildings and Facilities for Pharmacies etc.” Notification of Director-General of
Pharmaceutical Affairs Bureau, MHW, PAB No.1332 dated October 9, 1980.
“Points to Be Noted in Accreditation for Foreign Manufacturers of Quasi-drugs and
Cosmetics”, the Notification of Director of Evaluation & Licensing Division,
Pharmaceutical and Food Safety Bureau, MHLW, PFSB/ELD No. 0331018 dated
March 31, 2005.
“Documents to be Attached to Application for Accreditation of Foreign
Manufacturers of Medical Devices and In vitro Diagnostics”, the Notification of
Office director of Office of Medical Devices Evaluation, Evaluation & Licensing
Division, Pharmaceutical and Food Safety Bureau, MHLW, PFSB/ELD/MDE
No.0707001 dated July 7, 2005.
7. 7
“Q&As on Documents to be Attached to Application for Accreditation of Foreign
Manufacturers of Medical Devices and In vitro Diagnostics”, the Office
Communication Letter of Office of Medical Devices Evaluation, Evaluation &
Licensing Division, Pharmaceutical and Food Safety Bureau, MHLW; dated July 7,
2005.
“Documents to be Attached to Applications for Accreditation of Foreign
Manufacturers of Drugs and Quasi-drugs”, the Notification of Director of Evaluation
& Licensing Division, Pharmaceutical and Food Safety Bureau, MHLW; PFSB/ELD
No. 1024002 dated October 24, 2005.
“Q&As on Accreditation of Foreign Manufacturers”, Office Communication Letter of
Evaluation & Licensing Division, Pharmaceutical and Food Safety Bureau, MHLW;
dated February 14, 2006.
“Taxation on License and Accreditation of Manufacturers of Pharmaceuticals and
Medical Devices, etc.”, the Office Communication Letter of Evaluation & Licensing
Division, Pharmaceutical and Food Safety Bureau, MHLW; dated February 23,
2006.
“Administrative Procedure for License and Accreditation of Marketing Business of
Pharmaceuticals and Medical Devices etc. associated with Taxation on License and
Accreditation”, the Notification of Director of Evaluation & Licensing Division and
Director of Pharmaceutical and Food Safety Bureau, MHLW, PFSB/ELD No.
0331025, PFSB/SB No. 0331012 dated March 31, 2006.
“Q&As on Documents to be Attached to Application for Accreditation of Foreign
Manufacturers of Medical Devices and In vitro Diagnostics (No.2)”, Office
Communication Letter of Office of Medical Devices Evaluation, Evaluation &
Licensing Division, Pharmaceutical and Food Safety Bureau, MHLW; dated July 27,
2006.
“Forms to be Attached to Applications for Authorization of Manufacture of
Pharmaceuticals, etc and Accreditation of Foreign Manufacturers”, Notification of
the Director-General of Pharmaceutical and Food Safety Bureau, MHLW PFSB
No.0619002 dated June 19, 2007 (Written in Japanese but English forms are
8. 8
available)
“Handling of Application for Accreditation of Foreign Manufacturers” Notification of
Director of Evaluation and Licensing Division of Pharmaceutical and Food Safety
Bureau, MHLW, PFSB/ELD No.0619004 dated June 19, 2007
“Q&As on Approval Application for Pharmaceuticals,etc”, the Office Communication
Letter of Evaluation & Licensing Division, Pharmaceutical and Food Safety Bureau,
MHLW; dated June 19, 2007
“Accelerated procedures of change of manufacturing establishment or registration
of additional manufacturing establishment of OTC drugs“ Notification of Director of
the Evaluation and Licensing Division, Director of Compliance and Narcotics
Division, Pharmaceutical and Food Safety Bureau, MHLW, PFSB/ELD No.0620001,
PFSB/CND No. 0620009 dated June 20, 2007
9. 9
Examinations in Accreditation for Foreign Manufacturers
* In principle, document examination is required for accreditation
Applicant
(Foreign
Manufacturer)
Marketing
Approval
Holder
(1) Application to Minister
& Application for Examination
to Chief Executive, PMDA
(2) Examinations
(Document and On-site) *
(3) Inquiry, Advice,
and ReplacementOrder
(4) Response and
Replacement Notification
(7) Issue of Certificate
PMDA
(Application Received by)
Office of
Review Administration
Office of Compliance
and Standards
Office of
Review Administration
(6) Certificate
(5) Notification on Examination
Result & Application to Minister
ReplacementOrder,
when necessary
MHLW
Foreign
Manufacturing
Establishment